Efficient recovery of the immune system following bone marrow or stem cell transplantation requires optimal function of all obligatory supportive components of the marrow microenvironment. Work completed during previous periods of funding was focused on bone marrow stromal cells (BMSC) function subsequent to dose escalated chemotherapy. These studies demonstrated that BMSC VCAM-1 and CXCL-12 (SDF-1) proteins were diminished by VP-16 exposure. Treatment resulted in BMSC with reduced ability to support migration and survival of hematopoietic progenitor cells and dysregulation of expression and activity of BMSC derived matrix metalloproteinase-2 (MMP-2) and TGF-21. Experiments proposed in the current application extend these studies to osteoblasts as additional, essential constituents of the hematopoietic stem cell niche. Osteoblasts contribute to the """"""""endosteal niche"""""""" as the unique anatomical location in which stem cells are maintained until recruited into the proliferative population available for subsequent differentiation. Pilot data relevant to the current application indicate that primary human osteoblasts exposed to melphalan or VP-16 have diminished CXCL12 expression and chemotactic support and altered support of CD34+ bone marrow cell differentiation. Furthermore, phosphorlyated-Smad-2 signaling in osteoblasts is enhanced by direct exposure to chemotherapy, suggesting autocrine effects of therapy-induced TGF-b. The influence of chemotherapy induced autocrine signaling via elevated TGF-2 was investigated by treatment of primary human osteoblasts to rTGF-b which resulted in elevated TGF-2 gene expression, suggesting potential for amplification of the effects of elevated TGF-2 signaling. Recombinant TGF-2 also reduced CXCL12 expression and blunted chemotactic support. Building on these preliminary data we will investigate the effects of dose escalated chemotherapy on osteoblasts with evaluation of the mechanisms that underlie changes in factors necessary for optimal chemotactic support of CD34+ human hematopoietic stem cell maintenance, with emphasis on the mechanisms that underlie diminished CXCL-12 gene expression and protein levels (Aim 1). We will extend our model to three dimensional matrices to include consideration of signaling that is influenced by architecture, an important aspect of models to investigate osteoblast function in a chemotherapy stressed bone marrow microenvironment (Aim 2) and will transition our studies to a murine model in which the osteoblast population can be specifically identified by virtue of constitutive expression of GFP (Col2.3-GFP mice) to allow isolation and characterization of ostoeblasts from mice exposed to chemotherapy in vivo. Successful completion of these aims we will test the hypothesis that TGF-b is a critical mediator of the effects of dose escalated chemotherapy on dysregulation of osteoblast function in the bone marrow microenvironment. Completion of this study will contribute to development of strategies in which neutralization of TGF-b can be optimized to enhance long-term hematopoietic recovery of bone marrow transplantation patients which relies, in part, on optimal function of the stem cell niche.
Long term hematopoietic recovery following bone marrow transplantation relies on a functional stem cell niche in the bone marrow to which transplanted cells must efficiently migrate and are impacted on by diverse developmental cues. Osteoblasts of the endosteal niche define one essential population that supports stem cell development. In the current proposal we investigate their vulnerability to dose escalated chemotherapy.
|Moses, Blake S; Slone, William L; Thomas, Patrick et al. (2016) Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype. Exp Hematol 44:50-59.e2|
|Hare, Ian; Evans, Rebecca; Fortney, James et al. (2016) Chemotherapy-induced Dkk-1 expression by primary human mesenchymal stem cells is p53 dependent. Med Oncol 33:113|
|Moses, Blake S; Evans, Rebecca; Slone, William L et al. (2016) Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia. Mol Cancer Res 14:909-919|
|Slone, William L; Moses, Blake S; Hare, Ian et al. (2016) BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy. Oncotarget 7:23439-53|
|Hare, Ian; Gencheva, Marieta; Evans, Rebecca et al. (2016) In Vitro Expansion of Bone Marrow Derived Mesenchymal Stem Cells Alters DNA Double Strand Break Repair of Etoposide Induced DNA Damage. Stem Cells Int 2016:8270464|
|Slone, William L; Moses, Blake S; Evans, Rebecca et al. (2016) Modeling Chemotherapy Resistant Leukemia In Vitro. J Vis Exp :e53645|
|Rubenstein, Jon Nicholas; Beatty, Colleen; Kinkade, Zoe et al. (2015) Extranodal Marginal Zone Lymphoma of the Lung: Evolution from an Underlying Reactive Lymphoproliferative Disorder. J Clin Exp Pathol 5:|
|Aldawood, A M; Kinkade, Z; Rosado, F G et al. (2015) A Novel Method to Assess Bone Marrow Purity is Useful in Determining Blast Percentage by Flow Cytometry in Acute Myeloid Leukemia and Myelodysplasia. Ann Hematol Oncol 2:|
|Evans, R; Martin, K H; Moses, B S et al. (2015) Modeling The Bone Marrow Microenvironment's Influence on Leukemic Disease. Transl Biomed 6:|
|Jajosky, Audrey N; Coad, James E; Vos, Jeffrey A et al. (2014) RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression. Stem Cells Transl Med 3:836-48|
Showing the most recent 10 out of 31 publications